Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt

  • R. Tawil
  • J. Han
  • L. Wang
  • Vissing, John
  • B. van Engelen
  • J. Statland
  • M. Mellion
  • J. Shoskes
  • C. Morabito
  • J. Jiang
  • J. Webster
OriginalsprogEngelsk
ArtikelnummerP.136
TidsskriftNeuromuscular Disorders
Vol/bind32
Udgave nummerSupplement 1
Sider (fra-til)S104-S104
Antal sider1
ISSN0960-8966
DOI
StatusUdgivet - 2022
Begivenhed27th International Congress of the World-Muscle-Society (WMS) - Halifax, Canada
Varighed: 11 okt. 2022 → 15 okt. 2022

Konference

Konference27th International Congress of the World-Muscle-Society (WMS)
LandCanada
ByHalifax
Periode11/10/2022 → 15/10/2022

ID: 345419463